CRISPR/Cas-Based Nanobiosensor Using Plasmonic Nanomaterials to Detect Disease Biomarkers.

Area of Science:

• Biomedical Engineering
• Molecular Diagnostics
• Nanotechnology

Background:

• CRISPR/Cas gene-editing technology offers revolutionary potential for nucleic acid analysis.
• CRISPR/Cas systems are promising for biosensors due to collateral cleavage properties, but current designs have limitations.
• Existing CRISPR/Cas biosensors suffer from complexity, low sensitivity, selectivity, and signal-to-noise ratios.

Purpose of the Study:

• To review nanobiosensors integrating CRISPR/Cas systems with plasmonic nanomaterials.
• To explore how plasmonic nanomaterials can enhance CRISPR/Cas-based biosensing performance.
• To highlight advancements in developing highly sensitive CRISPR/Cas-based nanobiosensors for disease biomarker detection.

Main Methods:

• Review of interdisciplinary studies on CRISPR/Cas-based nanobiosensors.
• Integration of plasmonic nanomaterial characteristics with CRISPR/Cas systems.
• Analysis of enhanced signal amplification and sensitivity in nanobiosensor designs.

Main Results:

• Plasmonic nanomaterials can overcome limitations of traditional CRISPR/Cas biosensors.
• Enhanced sensitivity and signal-to-noise ratios are achieved through nanomaterial integration.
• CRISPR/Cas-based nanobiosensors demonstrate potential for detecting viral nucleic acids, small molecules, and proteins.

Conclusions:

• CRISPR/Cas systems combined with plasmonic nanomaterials offer a pathway to highly sensitive biosensors.
• These nanobiosensors can significantly improve molecular diagnostics for various disease biomarkers.
• This review inspires innovation in personalized medicine through advanced CRISPR/Cas and nanomaterial applications.